Prevalence and Odds of Anxiety Disorders and Anxiety Symptoms in Children and Adults with Psoriasis: Systematic Review and Meta-analysis


  • Isabelle Jalenques Adult Psychiatry and Medical Psychology Department, CHU Clermont-Ferrand, 58 rue Montalembert, FR-63003 Clermont-Ferrand Cedex 1, France
  • Fabien Bourlot CHU Clermont-Ferrand, Service de Psychiatrie de l’Adulte A et Psychologie Médicale, F-63000 Clermont-Ferrand, France
  • Elisa Martinez CHU Clermont-Ferrand, Service de Psychiatrie de l’Adulte A et Psychologie Médicale, F-63000 Clermont-Ferrand, France
  • Bruno Pereira CHU Clermont-Ferrand, Direction de la Recherche Clinique et de l’Innovation, F-63000 Clermont-Ferrand, France
  • Michel D'Incan Clermont Auvergne Université, INSERM, CHU Clermont-Ferrand, Service de Dermatologie, Clermont Auvergne INP, Institut Pascal, F-63000 Clermont-Ferrand, France
  • Sophie Lauron CHU Clermont-Ferrand, Service de Psychiatrie de l’Adulte A et Psychologie Médicale, F-63000 Clermont-Ferrand, France
  • Fabien Rondepierre CHU Clermont-Ferrand, Service de Psychiatrie de l’Adulte A et Psychologie Médicale, F-63000 Clermont-Ferrand, France



Psoriasis, Anxiety disorders, Anxiety symptoms, Systematic review, Meta-analysis


The magnitude of the association between psoriasis and depression has been evaluated, but not that between psoriasis and anxiety. The aim of this systematic review and meta-analysis was to examine the prevalence and odds of anxiety disorders and symptoms in patients with psoriasis. Five medical databases (Cochrane Database, EMBASE, PubMed, PsychINFO, ScienceDirect) were searched for relevant literature. A total of 101 eligible articles were identified. Meta-analysis revealed different prevalence rates depending on the type of anxiety disorder: 15% [95% confidence interval [CI] 9–21] for social anxiety disorder, 11% [9–14] for generalized anxiety disorder, and 9% [95% CI 8–10] for unspecified anxiety disorder. There were insufficient studies assessing other anxiety disorders to be able to draw any conclusions on their true prevalence. Meta-analysis also showed a high prevalence of anxiety symptoms (34% [95% CI 32–37]). Case-control studies showed a positive association between psoriasis and unspecified anxiety disorder (odds ratio 1.48 [1.18; 1.85]) and between psoriasis and anxiety symptoms (odds ratio 2.51 [2.02; 3.12]). All meta-analyses revealed an important heterogeneity, which could be explained in each case by methodological factors. The results of this study raise the necessity of screening for the presence of anxiety disorders, as previously recommended for depressive disorders, in patients with psoriasis and, if necessary, to refer such patients for evaluation by a mental health professional and appropriate treatment.


Download data is not yet available.


Lee S, Lee H, Lee CH, Lee W-S. Comorbidities in alopecia areata: a systematic review and meta-analysis. J Am Acad Dermatol 2019; 80: 466-477. DOI:

Okhovat J-P, Marks DH, Manatis-Lornell A, Hagigeorges D, Locascio JJ, Senna MM. Association between alopecia areata, anxiety, and depression: a systematic review and meta-analysis. J Am Acad Dermatol 2019 Jun 1 [Epub ahead of print]. DOI:

Rønnstad ATM, Halling-Overgaard A-S, Hamann CR, Skov L, Egeberg A, Thyssen JP. Association of atopic dermatitis with depression, anxiety, and suicidal ideation in children and adults: a systematic review and meta-analysis. J Am Acad Dermatol 2018; 79: 448-456. DOI:

Machado MO, Stergiopoulos V, Maes M, Kurdyak PA, Lin P-Y, Wang L-J, et al. Depression and anxiety in adults with hidradenitis suppurativa: a systematic review and meta-analysis. JAMA Dermatol 2019; 155: 939-945. DOI:

Patel KR, Lee HH, Rastogi S, Vakharia PP, Hua T, Chhiba K, et al. Association between hidradenitis suppurativa, depression, anxiety, and suicidality: a systematic review and meta-analysis. J Am Acad Dermatol 2019; 83: 737-744. DOI:

Jalenques I, Ciortianu L, Pereira B, D'Incan M, Lauron S, Rondepierre F. The prevalence and odds of anxiety and depression in children and adults with hidradenitis suppurativa: systematic review and meta-analyses. J Am Acad Dermatol 2020; 83: 542-553. DOI:

Konstantinou GN, Konstantinou GN. Psychiatric comorbidity in chronic urticaria patients: a systematic review and meta-analysis. Clin Transl Allergy 2019; 9: 42. DOI:

American Psychiatrist Association. Diagnostic and Statistical Manual of Mental Disorders (DSM). Fifth Edition. Washington, D.C., American Psychiatrist Association; 2013.

World Health Organization (WHO. The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. Geneva: World Health Organization; 1992, p. 377.

Parisi R, Symmons DPM, Griffiths CEM, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013; 133: 377-385. DOI:

Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol 2017; 31: 205-212. DOI:

Dowlatshahi EA, Wakkee M, Arends LR, Nijsten T. The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis. J Invest Dermatol 2014; 134: 1542-1551. DOI:

Chi C-C, Chen T-H, Wang S-H, Tung T-H. Risk of suicidality in people with psoriasis: a systematic review and meta-analysis of cohort studies. Am J Clin Dermatol 2017; 18: 621-627. DOI:

Fleming P, Bai JW, Pratt M, Sibbald C, Lynde C, Gulliver WP. The prevalence of anxiety in patients with psoriasis: a systematic review of observational studies and clinical trials. J Eur Acad Dermatol Venereol 2017; 31: 798-807. DOI:

Ferreira BR, Pio-Abreu JL, Reis JP, Figueiredo A. Analysis of the prevalence of mental disorders in psoriasis: the relevance of psychiatric assessment in dermatology. Psychiatr Danub 2017; 29: 401-406. DOI:

Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009; 339: b2700. DOI:

Hoy D, Brooks P, Woolf A, Blyth F, March L, Bain C, et al. Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. J Clin Epidemiol 2012; 65: 934-939. DOI:

Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 1998; 17: 857-872.<857::AID-SIM777>3.0.CO;2-E DOI:<857::AID-SIM777>3.0.CO;2-E

DerSimonian R, Laird N. Meta-analysis in clinical trials revisited. Contemp Clin Trials 2015; 45: 139-145. DOI:

Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560. DOI:

Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634. DOI:

Sterne JAC, Sutton AJ, Ioannidis JPA, Terrin N, Jones DR, Lau J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 2011; 343: d4002-d4002. DOI:

Saraceno R, Saraceno R, Faleri S, Ruzzetti M, Centonze D, Chimenti S. Prevalence and management of panic attacks during infliximab infusion in psoriatic patients. DRM 2012; 225: 236-241. DOI:

Sanna L, Stuart AL, Pasco JA, Kotowicz MA, Berk M, Girardi P, et al. Physical comorbidities in men with mood and anxiety disorders: a population-based study. BMC Med 2013; 11: 110. DOI:

Strober B, Karki C, Mason M, Guo N, Holmgren SH, Greenberg JD, et al. Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: results from the Corrona Psoriasis Registry. J Am Acad Dermatol 2018; 78: 323-332. DOI:

Kara T, Topkarcı Z, Yılmaz S, Akaltun İ, Erdoğan B. Pediatric patients with psoriasis and psychiatric disorders: premorbidity and comorbidity in a case-control study. J Dermatolog Treat 2019; 30: 129-134. DOI:

Lyketsos CG, Lyketsos GC, Richardson SC, Beis A. Dysthymic states and depressive syndromes in physical conditions of presumably psychogenic origin. Acta Psychiatr Scand 1987; 76: 529-534. DOI:

Mazzetti M, Mozzetta A, Soavi GC, Andreoli E, Foglio Bonda PG, Puddu P, et al. Psoriasis, stress and psychiatry: psychodynamic characteristics of stressors. Acta Derm Venereol 1994; 186: 62-64.

Consoli SM, Rolhion S, Martin C, Ruel K, Cambazard F, Pellet J, et al. Low levels of emotional awareness predict a better response to dermatological treatment in patients with psoriasis. Dermatology 2006; 212: 128-136. DOI:

Mehta V, Malhotra SK. Psychiatric evaluation of patients with psoriasis vulgaris and chronic urticaria. German J Psychiatr 2007; 10: 104-110.

Biljan D, Laufer D, Filaković P, Situm M, Brataljenović T. Psoriasis, mental disorders and stress. Coll Antropol 2009; 33: 889-892.

Golpour M, Hosseini SH, Khademloo M, Ghasemi M, Ebadi A, Koohkan F, et al. Depression and anxiety disorders among patients with psoriasis: a hospital-based case-control study. Dermatol Res Pract 2012; 2012: 381905. DOI:

Luca M, Luca A, Musumeci ML, Fiorentini F, Micali G, Calandra C. Psychopathological variables and sleep quality in psoriatic patients. Int J Mol Sci 2016; 17: 1184. DOI:

Łakuta P, Przybyła-Basista H. Toward a better understanding of social anxiety and depression in psoriasis patients: The role of determinants, mediators, and moderators. J Psychosom Res 2017; 94: 32-38. DOI:

Belvisi D, Berardelli I, Ferrazzano G, Costanzo M, Corigliano V, Fabbrini G, et al. The clinical correlates of suicidal ideation in Parkinson's disease. Parkinsonism Relat Disord 2019; 63: 54-59. DOI:

Leisner MZ, Riis JL, Schwartz S, Iversen L, Østergaard SøD, Olsen MS. Psoriasis and risk of mental disorders in Denmark. JAMA Dermatol 2019; 155: 745-747. DOI:

Rayner L, Matcham F, Hutton J, Stringer C, Dobson J, Steer S, et al. Embedding integrated mental health assessment and management in general hospital settings: feasibility, acceptability and the prevalence of common mental disorder. Gen Hosp Psychiatry 2014; 36: 318-324. DOI:

Lakshmy S, Balasundaram S, Sarkar S, Audhya M, Subramaniam E. A cross-sectional study of prevalence and implications of depression and anxiety in psoriasis. Indian J Psychol Med 2015; 37: 434. DOI:

Li X, Luo D, Qiu Y, Chen M, Su J, Yi M. [Characteristics of health seeking behaviors for patients with psoriasis in a general hospital]. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2016; 41: 612-618 (in Chinese).

Jain N, Bukharia A, Khess CRJ, Munda SK. Psychiatric morbidity among patients with psoriasis and acne: a comparative study. J Pak Assoc Dermatol 2017; 26: 337-346.

Lamb RC, Matcham F, Turner MA, Rayner L, Simpson A, Hotopf M, et al. Screening for anxiety and depression in people with psoriasis: a cross-sectional study in a tertiary referral setting. Br J Dermatol 2017; 176: 1028-1034. DOI:

Tian Z, Huang Y, Yue T, Zhou J, Tao L, Han L, et al. A Chinese cross-sectional study on depression and anxiety symptoms in patients with psoriasis vulgaris. Psychol Health Med 2019; 24: 269-280. DOI:

Han C, Lofland JH, Zhao N, Schenkel B. Increased prevalence of psychiatric disorders and health care-associated costs among patients with moderate-to-severe psoriasis. J Drugs Dermatol 2011; 10: 843-850.

Lan C-CE, Yu H-S, Li W-C, Ko Y-C, Wu C-S, Lu Y-W, et al. Anxiety contributes to the development of cerebrovascular disease in Taiwanese patients with psoriasis: a population-based study. Eur J Dermatol 2013; 23: 290-292. DOI:

Kimball AB, Leonardi C, Stahle M, Gulliver W, Chevrier M, Fakharzadeh S, et al. Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR). Br J Dermatol 2014; 171: 137-147. DOI:

Sahiner IV, Taskintuna N, Sevik AE, Kose OK, Atas H, Sahiner S, et al. The impact role of childhood traumas and life events in patients with alopecia aerate and psoriasis. J Psychiatry 2014; 17: 6. DOI:

Sanchez-Carazo JL, López-Estebaranz JL, Guisado C. Comorbidities and health-related quality of life in Spanish patients with moderate to severe psoriasis: a cross-sectional study (Arizona study). J Dermatol 2014; 41: 673-678. DOI:

Feldman SR, Zhao Y, Shi L, Tran MH. Economic and comorbidity burden among patients with moderate-to-severe psoriasis. J Manag Care Spec Pharm 2015; 21: 874-888. DOI:

Karia SB, De Sousa A, Shah N, Sonavane S, Bharati A. Psychiatric morbidity and quality of life in skin diseases: a comparison of alopecia areata and psoriasis. Ind Psychiatry J 2015; 24: 125-128. DOI:

Offidani E, Del Basso D, Prignago F, Tomba E. Discriminating the presence of psychological distress in patients suffering from psoriasis: an application of the clinimetric approach in dermatology. Acta Derm Venereol 2016; 96: 69-73.

Armstrong AW, Zhao Y, Herrera V, Li Y, Bancroft T, Hull M, et al. Drivers of healthcare costs among the costliest patients with psoriasis over three years in a United States health plan. J Drugs Dermatol 2017; 16: 651-658.

Sorour F, Abdelmoaty A, Bahary MH, El Birqdar B. Psychiatric disorders associated with some chronic dermatologic diseases among a group of Egyptian dermatology outpatient clinic attendants. J Egypt Womens Dermatol Soc 2017; 14: 31-36. DOI:

Feldman SR, Hur P, Zhao Y, Tian H, Wei Z, Wang X, et al. Incidence rates of comorbidities among patients with psoriasis in the United States. Dermatol Online J 2018; 24: 13030/qt2m18n6vj. DOI:

Galili E, Barzilai A, Shreberk-Hassidim R, Merdler I, Caspi T, Astman N. Neuropsychiatric comorbidity among adolescents with psoriasis. Br J Dermatol 2018; 178: 910-916. DOI:

Huilaja L, Tiri H, Jokelainen J, Timonen M, Tasanen K. Patients with hidradenitis suppurativa have a high psychiatric disease burden: a Finnish nationwide registry study. J Invest Dermatol 2018; 138: 46-51. DOI:

Strober B, Gooderham M, de Jong EMGJ, Kimball AB, Langley RG, Lakdawala N, et al. Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Am Acad Dermatol 2018; 78: 70-80. DOI:

Bang CH, Yoon JW, Chun JH, Han JH, Park YM, Lee SJ, et al. Association of psoriasis with mental health disorders in South Korea. JAMA Dermatol 2019; 155: 747-749. DOI:

Paller AS, Schenfeld J, Accortt NA, Kricorian G. A retrospective cohort study to evaluate the development of comorbidities, including psychiatric comorbidities, among a pediatric psoriasis population. Pediatr Dermatol 2019; 36: 290-297. DOI:

Parisi R, Webb RT, Kleyn CE, Carr MJ, Kapur N, Griffiths CEM, et al. Psychiatric morbidity and suicidal behaviour in psoriasis: a primary care cohort study. Br J Dermatol 2019; 180: 108-115. DOI:

Patel KR, Lee HH, Rastogi S, Singam V, Vakharia PP, Silverberg JI. Association of psoriasis with psychiatric hospitalization in United States children and adults. Dermatology 2019; 235: 276-286. DOI:

Tzur Bitan D, Krieger I, Comaneshter D, Cohen AD, Feingold D. The association between the socioeconomic status and anxiety-depression comorbidity in patients with psoriasis: a nationwide population-based study. J Eur Acad Dermatol Venereol 2019; 33: 1555-1561. DOI:

Jowett S, Ryan T. Skin disease and handicap: an analysis of the impact of skin conditions. Soc Sci Med 1985; 20: 425-429. DOI:

Price ML, Mottahedin I, Mayo PR. Can psychotherapy help patients with psoriasis? Clin Exp Dermatol 1991; 16: 114-117. DOI:

Finzi AF, Polenghi MM, Guzzi R, Rebecchi I. Psychosomatic dermatology: the Milan experience. Ann Ital Dermatol Clin Sper 1993; 47: 7-11.

Scharloo M, Kaptein AA, Weinman J, Bergman W, Vermeer BJ, Rooijmans HGM. Patients' illness perceptions and coping as predictors of functional status in psoriasis: a 1-year follow-up: illness perceptions and coping in psoriasis. Br J Dermatol 2000; 142: 899-907. DOI:

Kent G, Keohane S. Social anxiety and disfigurement: the moderating effects of fear of negative evaluation and past experience. Br J Clin Psychol 2001; 40: 23-34. DOI:

Richards HL, Fortune DG, Griffiths CEM, Main CJ. The contribution of perceptions of stigmatisation to disability in patients with psoriasis. J Psychosom Res 2001; 50: 11-15. DOI:

Hill L, Kennedy P. The role of coping strategies in mediating subjective disability in people who have psoriasis. Psychol Health Med 2002; 7: 261-269. DOI:

Fortune DG, Richards HL, Corrin A, Taylor RJ, Griffiths CE, Main CJ. Attentional bias for psoriasis-specific and psychosocial threat in patients with psoriasis. J Behav Med 2003; 26: 211-224. DOI:

Kowacs F, Socal M, Ziomkowski S, Borges-Neto V, Toniolo D, Francesconi C, et al. Symptoms of depression and anxiety, and screening for mental disorders in migrainous patients. Cephalalgia 2003; 23: 79-89. DOI:

Fortune DG, Richards HL, Kirby B, McElhone K, Main CJ, Griffiths CEM. Successful treatment of psoriasis improves psoriasis-specific but not more general aspects of patients' well-being. Br J Dermatol 2004; 151: 1219-1226. DOI:

Richards HL, Fortune DG, Weidmann A, Sweeney SKT, Griffiths CEM. Detection of psychological distress in patients with psoriasis: low consensus between dermatologist and patient. Br J Dermatol 2004; 151: 1227-1233. DOI:

Richards HL, Fortune DG, Chong SLP, Mason DL, Sweeney SKT, Main CJ, et al. Divergent beliefs about psoriasis are associated with increased psychological distress. J Invest Dermatol 2004; 123: 49-56. DOI:

Fortune DG, Richards HL, Griffiths CEM, Main CJ. Worry and pathological worry in patients with psoriasis: cross sectional and longitudinal analyses of the Penn State Worry Questionnaire (PSWQ) in four samples of patients. J Clin Psychol Med Settings 2005; 12: 143-152. DOI:

Fortune DG, Richards HL, Griffiths CEM. Psychologic factors in psoriasis: consequences, mechanisms, and interventions. Dermatol Clint 2005; 23: 681-694. DOI:

Yang Y, Koh D, Khoo L, Nyunt SZ, Ng V, Goh CL. The psoriasis disability index in Chinese patients: contribution of clinical and psychological variables. Int J Dermatol 2005; 44: 925-929. DOI:

Gaikwad R, Deshpande S, Raje S, Dhamdhere DV, Ghate MR. Evaluation of functional impairment in psoriasis. Indian J Dermatol Venereol Leprol 2006; 72: 37-40. DOI:

Schneider G, Hockmann J, Ständer S, Luger TA, Heuft G. Psychological factors in prurigo nodularis in comparison with psoriasis vulgaris: results of a case-control study. Br J Dermatol 2006; 154: 61-66. DOI:

Hawro T, Miniszewska J, Chodkiewicz J, Sysa-Jedrzejowska A, Zalewska A. [Anxiety, depression and social support in patients with psoriasis]. Prz Lek 2007; 64: 568-571 (in Polish).

Kirby B, Richards HL, Mason DL, Fortune DG, Main CJ, Griffiths CEM. Alcohol consumption and psychological distress in patients with psoriasis. Br J Dermatol 2008; 158: 138-140.

Daudén E, Griffiths CEM, Ortonne J-P, Kragballe K, Molta CT, Robertson D, et al. Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study. J Eur Acad Dermatol Venereol 2009; 23: 1374-1382. DOI:

Langley RG, Feldman SR, Han C, Schenkel B, Szapary P, Hsu M-C, et al. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: results from a randomized, double-blind, placebo-controlled phase III trial. J Am Acad Dermatol 2010; 63: 457-465. DOI:

Chern E, Yau D, Ho J-C, Wu W-M, Wang C-Y, Chang H-W, et al. Positive effect of modified Goeckerman regimen on quality of life and psychosocial distress in moderate and severe psoriasis. Acta Derm Venereol 2011; 91: 447-451. DOI:

McAleer MA, Mason DL, Cunningham S, O'Shea SJ, McCormick PA, Stone C, et al. Alcohol misuse in patients with psoriasis: identification and relationship to disease severity and psychological distress. Br J Dermatol 2011; 164: 1256-1261. DOI:

Darwazeh AM, Al-Aboosi MM, Bedair AA. Prevalence of oral mucosal lesions in psoriatic patients: a controlled study. J Clin Exp Dent 2012; 4: e286-291. DOI:

Gniadecki R, Robertson D, Molta CT, Freundlich B, Pedersen R, Li W, et al. Self-reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etanercept regimens. J Eur Acad Dermatol Venereol 2012; 26: 1436-1443. DOI:

Mizara A, Papadopoulos L, McBride SR. Core beliefs and psychological distress in patients with psoriasis and atopic eczema attending secondary care: the role of schemas in chronic skin disease. Br J Dermatol 2012; 166: 986-993. DOI:

Karababa F, Yesilova Y, Turan E, Selek S, Altun H, Selek S. Impact of depressive symptoms on oxidative stress in patients with psoriasis. Redox Rep 2013; 18: 51-55. DOI:

Pujol RM, Puig L, Daudén E, Sánchez-Carazo JL, Toribio J, Vanaclocha F, et al. Mental health self-assessment in patients with moderate to severe psoriasis: an observational, multicenter study of 1164 patients in Spain (the VACAP Study). Actas Dermosifiliogr 2013; 104: 897-903. DOI:

Cepuch G, Wojtas K, Zych B, Matuszewska B. Assessment of emotional state of psoriasis patients and the degree of acceptance of the disease. Fam Med Prim Care Rev 2014; 2: 85-87.

Bangemann K, Schulz W, Wohlleben J, Weyergraf A, Snitjer I, Werfel T, et al. Depression und Angststörung bei Psoriasispatienten: Schutz- und Risikofaktoren. Hautarzt 2014; 65: 1056-1061. DOI:

Korkoliakou P, Christodoulou C, Kouris A, Porichi E, Efstathiou V, Kaloudi E, et al. Alexithymia, anxiety and depression in patients with psoriasis: a case-control study. Ann Gen Psychiatry 2014; 13: 38. DOI:

McDonough E, Ayearst R, Eder L, Chandran V, Rosen CF, Thavaneswaran A, et al. Depression and anxiety in psoriatic disease: prevalence and associated factors. J Rheumatol 2014; 41: 887-896. DOI:

Molina-Leyva A, Almodovar-Real A, Ruiz-Carrascosa JC, Naranjo-Sintes R, Serrano-Ortega S, Jimenez-Moleon JJ. Distribution pattern of psoriasis affects sexual function in moderate to severe psoriasis: a prospective case series study. J Sex Med 2014; 11: 2882-2889. DOI:

AlShahwan MA. The prevalence of anxiety and depression in Arab dermatology patients. J Cutan Med Surg 2015; 19: 297-303. DOI:

Biçici F, Berksoy Hayta S, Akyol M, Özçelik S, Çınar Z. Evaluation of sleep quality in patients with psoriasis. Turkderm 2015; 49: 208-212. DOI:

Dalgard FJ, Gieler U, Tomas-Aragones L, Lien L, Poot F, Jemec GBE, et al. The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J Invest Dermatol 2015; 135: 984-991. DOI:

Iskandar IYK, Ashcroft DM, Warren RB, Yiu ZZN, McElhone K, Lunt M, et al. Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions Register. Br J Dermatol 2015; 173: 510-518. DOI:

Molina-Leyva A, Almodovar-Real A, Carrascosa JC-R, Molina-Leyva I, Naranjo-Sintes R, Jimenez-Moleon JJ. Distribution pattern of psoriasis, anxiety and depression as possible causes of sexual dysfunction in patients with moderate to severe psoriasis. An Bras Dermatol 2015; 90: 338-345. DOI:

Pärna E, Aluoja A, Kingo K. Quality of life and emotional state in chronic skin disease. Acta Derm Venereol 2015; 95: 312-316. DOI:

Tsintsadze N, Beridze L, Tsintsadze N, Krichun Y, Tsivadze N, Tsintsadze M. Psychosomatic aspects in patients with dermatologic diseases. Georgian Med News 2015; 243: 70-75.

Abebe G, Ayano G. Prevalence and factors associated with anxiety among patients with common skin disease on follow up at alert referral hospital, Addis Ababa, Ethiopia. J Psychiatry 2016; 19: 367. DOI:

Innamorati M, Quinto RM, Imperatori C, Lora V, Graceffa D, Fabbricatore M, et al. Health-related quality of life and its association with alexithymia and difficulties in emotion regulation in patients with psoriasis. Compr Psychiatry 2016; 70: 200-208. DOI:

Petraškienė R, Valiukevičienė S, Macijauskienė J. Associations of the quality of life and psychoemotional state with sociodemographic factors in patients with psoriasis. Medicina 2016; 52: 238-243. DOI:

Tee SI, Lim ZV, Theng CT, Chan KL, Giam YC. A prospective cross-sectional study of anxiety and depression in patients with psoriasis in Singapore. J Eur Acad Dermatol Venereol 2016; 30: 1159-1164. DOI:

Eckert L, Gupta S, Amand C, Gadkari A, Mahajan P, Gelfand JM. Impact of atopic dermatitis on health-related quality of life and productivity in adults in the United States: an analysis using the National Health and Wellness Survey. J Am Acad Dermatol 2017; 77: 274-279. DOI:

Kwan Z, Bong YB, Tan LL, Lim SX, Yong ASW, Ch'ng CC, et al. Socioeconomic and sociocultural determinants of psychological distress and quality of life among patients with psoriasis in a selected multi-ethnic Malaysian population. Psychol Health Med 2017; 22: 184-195. DOI:

Mendelson MH, Bernstein JA, Gabriel S, Balp M-M, Tian H, Vietri J, et al. Patient-reported impact of chronic urticaria compared with psoriasis in the United States. J Dermatolog Treat 2017; 28: 229-236. DOI:

Pompili M, Innamorati M, Forte A, Erbuto D, Lamis DA, Narcisi A, et al. Psychiatric comorbidity and suicidal ideation in psoriasis, melanoma and allergic disorders. Int J Psychiatry Clin Pract 2017; 21: 209-214. DOI:

Balp MM, Khalil S, Tian H, Gabriel S, Vietri J, Zuberbier T. Burden of chronic urticaria relative to psoriasis in five European countries. J Eur Acad Dermatol Venereol 2018; 32: 282-290. DOI:

Gordon KB, Armstrong AW, Han C, Foley P, Song M, Wasfi Y, et al. Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study. J Eur Acad Dermatol Venereol 2018; 32: 1940-1949. DOI:

Innamorati M, Quinto RM, Lester D, Iani L, Graceffa D, Bonifati C. Cognitive impairment in patients with psoriasis: a matched case-control study. J Psychosom Res 2018; 105: 99-105. DOI:

Madrid Álvarez MB, Carretero Hernández G, González Quesada A, González Martín JM. Measurement of the psychological impact of psoriasis on patients receiving systemic treatment. Actas Dermosifiliogr 2018; 109: 733-740. DOI: DOI:

Romiti R, Fabrício LHZ, Souza C da S, Galvão LO, de Castro CCS, Terena AC, et al. Assessment of psoriasis severity in Brazilian patients with chronic plaque psoriasis attending outpatient clinics: a multicenter, population-based cross-sectional study (APPISOT). J Dermatolog Treat 2018; 29: 775-785. DOI:

Alariny AF, Farid CI, Elweshahi HM, Abbood SS. Psychological and sexual consequences of psoriasis vulgaris on patients and their partners. J Sex Med 2019; 16: 1900-1911. DOI:

Deveci E, Kocacenk T, Şahan E, Yılmaz O, Öztürk A, Kırpınar İ. Oxidative stress and inflammatory response in patients with psoriasis; is there any relationship with psychiatric comorbidity and cognitive functions? Psychiatry Clin Psychopharmacol 2019; 29: 682-695. DOI:

Jin W, Zhang S, Duan Y. Depression symptoms predict worse clinical response to etanercept treatment in psoriasis patients. Dermatology 2019; 235: 55-64. DOI:

Leman J, Walton S, Layton AM, Ward KA, McBride S, Cliff S, et al. The realworld impact of adalimumab on quality of life and the physical and psychological effects of moderate-to-severe psoriasis: a UK prospective, multicenter, observational study. J Dermatolog Treat 2020; 31: 213-221. DOI:

Lopes N, Dias LLS, Azulay-Abulafia L, Oyafuso LKM, Suarez MV, Fabricio L, et al. Humanistic and economic impact of moderate to severe plaque psoriasis in Brazil. Adv Ther 2019; 36: 2849-2865. DOI:

Martínez-Ortega JM, Nogueras P, Muñoz-Negro JE, Gutiérrez-Rojas L, González-Domenech P, Gurpegui M. Quality of life, anxiety and depressive symptoms in patients with psoriasis: a case-control study. J Psychosom Res 2019; 124: 109780. DOI:

Nearchou F, D'Alton P, Donnelly A, O'Driscoll L, O'Flanagan S, Kirby B. Validation and psychometric evaluation of a brief screening questionnaire for psychological distress in patients with psoriasis. J Eur Acad Dermatol Venereol 2019; 33: 1325-1330. DOI:

Reich K, Foley P, Han C, McElligott S, Muser E, Li N, et al. Guselkumab improves work productivity in patients with moderate-to-severe psoriasis with or without depression and anxiety: results from the VOYAGE 2 comparator study versus adalimumab. J Dermatolog Treat 2020; 31: 617-623. DOI:

Sampogna F, Puig L, Spuls P, Girolomoni G, Radtke MA, Kirby B, et al. Reversibility of alexithymia with effective treatment of moderate-to-severe psoriasis: longitudinal data from EPIDEPSO. Br J Dermatol 2019; 180: 397-403. DOI:

Yang A, Xin X, Yang W, Li M, Li L, Liu X. L'étanercept réduit l'anxiété et la dépression chez les patients atteints de psoriasis, et la dépression chronique est corrélée à la réduction de la réponse à l'étanercept. Ann Dermatol Venereol 2019; 146: 363-371. DOI:

Zhang Q, Han J, Zhang Y, Li C, Chen P, Zhang J, et al. Study on the psychological health and related risk factors in 245 patients with psoriasis in Inner Mongolia. Psychol Health Med 2019; 24: 769-780. DOI:

Demet MM, Deveci A, Taskin EO, Ermertcan AT, Yurtsever F, Deniz F, et al. Obsessive-compulsive disorder in a dermatology outpatient clinic. Gen Hosp Psychiatry 2005; 27: 426-430. DOI:

Remes O, Brayne C, van der Linde R, Lafortune L. A systematic review of reviews on the prevalence of anxiety disorders in adult populations. Brain Behav 2016; 6: e00497. DOI:

Baxter AJ, Scott KM, Vos T, Whiteford HA. Global prevalence of anxiety disorders: a systematic review and meta-regression. Psychol Med 2013; 43: 897-910. DOI:

Jalenques I, Rondepierre F, Massoubre C, Haffen E, Grand JP, Labeille B, et al. High prevalence of psychiatric disorders in patients with skin-restricted lupus: a case-control study. Br J Dermatol 2016; 174: 1051-1060. DOI:




How to Cite

Jalenques, I., Bourlot, F., Martinez, E., Pereira, B., D’Incan, M., Lauron, S., & Rondepierre, F. (2022). Prevalence and Odds of Anxiety Disorders and Anxiety Symptoms in Children and Adults with Psoriasis: Systematic Review and Meta-analysis. Acta Dermato-Venereologica, 102, adv00769.